- Home
- FFC vs NUVB Comparison
FFC vs NUVB Comparison
Compare FFC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFC
- NUVB
- Stock Information
- Founded
- FFC 1983
- NUVB 2018
- Country
- FFC United States
- NUVB United States
- Employees
- FFC N/A
- NUVB N/A
- Industry
- FFC Trusts Except Educational Religious and Charitable
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- FFC Finance
- NUVB Health Care
- Exchange
- FFC Nasdaq
- NUVB Nasdaq
- Market Cap
- FFC 767.5M
- NUVB 679.9M
- IPO Year
- FFC N/A
- NUVB N/A
- Fundamental
- Price
- FFC $15.06
- NUVB $1.97
- Analyst Decision
- FFC
- NUVB Strong Buy
- Analyst Count
- FFC 0
- NUVB 5
- Target Price
- FFC N/A
- NUVB $8.00
- AVG Volume (30 Days)
- FFC 164.1K
- NUVB 3.3M
- Earning Date
- FFC 01-01-0001
- NUVB 05-13-2025
- Dividend Yield
- FFC 6.79%
- NUVB N/A
- EPS Growth
- FFC N/A
- NUVB N/A
- EPS
- FFC N/A
- NUVB N/A
- Revenue
- FFC N/A
- NUVB $7,873,000.00
- Revenue This Year
- FFC N/A
- NUVB $75.73
- Revenue Next Year
- FFC N/A
- NUVB $440.21
- P/E Ratio
- FFC N/A
- NUVB N/A
- Revenue Growth
- FFC N/A
- NUVB N/A
- 52 Week Low
- FFC $11.90
- NUVB $1.54
- 52 Week High
- FFC $14.96
- NUVB $3.97
- Technical
- Relative Strength Index (RSI)
- FFC 43.57
- NUVB 52.62
- Support Level
- FFC $14.60
- NUVB $1.82
- Resistance Level
- FFC $15.26
- NUVB $2.08
- Average True Range (ATR)
- FFC 0.36
- NUVB 0.18
- MACD
- FFC -0.02
- NUVB 0.04
- Stochastic Oscillator
- FFC 46.74
- NUVB 79.63
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).